

Special Issue

Clinical Advances in Traumatic Brain Injury and Concussion

Message from the Guest Editor

The worldwide prevalence of traumatic brain injury (TBI) across the severity spectrum is growing at a rapid pace and is recognized as a significant public health concern. These injuries frequently result in a heterogeneous constellation of post-injury consequences, including structural and functional brain alterations and neurocognitive, psychiatric, and vestibular/balance sequelae. Due to these between- and within-patient differences in TBI outcomes, effective treatment by physicians, psychologists, therapists, and other relevant providers requires a personalized, patient-oriented approach. This Special Issue aims to familiarize clinicians and researchers with the latest advances in the translational research on TBI across the severity spectrum (e.g., mild/concussion, moderate, and severe) from the perspective of personalized medicine.

In this Special Issue, original research articles and reviews are welcome. Research areas may include, but are not limited to, the following, please see the website: https://www.mdpi.com/journal/jpm/special_issues/IY6844DN72

Guest Editor

Dr. Spencer W. Liebel

Department of Neurology, Traumatic Brain Injury and Concussion Center, University of Utah, 30 N 1900 E, Salt Lake City, UT, USA

Deadline for manuscript submissions

31 August 2026



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/si/200937](https://www.mdpi.com/si/200937)

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

[mdpi.com/journal/
jpm](https://www.mdpi.com/journal/jpm)





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/journal/

jpm



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).